New Therapeutic Targets for Mood Disorders
Existing pharmacological treatments for bipolar disorder (BPD) and major depressive disorder (MDD) are often insufficient for many patients. Here we describe a number of targets/compounds that clinical and preclinical studies suggest could result in putative novel treatments for mood disorders. Thes...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/tsw.2010.65 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552286075748352 |
|---|---|
| author | Rodrigo Machado-Vieira Giacomo Salvadore Nancy DiazGranados Lobna Ibrahim David Latov Cristina Wheeler-Castillo Jacqueline Baumann Ioline D. Henter Carlos A. Zarate |
| author_facet | Rodrigo Machado-Vieira Giacomo Salvadore Nancy DiazGranados Lobna Ibrahim David Latov Cristina Wheeler-Castillo Jacqueline Baumann Ioline D. Henter Carlos A. Zarate |
| author_sort | Rodrigo Machado-Vieira |
| collection | DOAJ |
| description | Existing pharmacological treatments for bipolar disorder (BPD) and major depressive disorder (MDD) are often insufficient for many patients. Here we describe a number of targets/compounds that clinical and preclinical studies suggest could result in putative novel treatments for mood disorders. These include: (1) glycogen synthase kinase-3 (GSK-3) and protein kinase C (PKC), (2) the purinergic system, (3) histone deacetylases (HDACs), (4) the melatonergic system, (5) the tachykinin neuropeptides system, (6) the glutamatergic system, and (7) oxidative stress and bioenergetics. The paper reviews data on new compounds that have shown antimanic or antidepressant effects in subjects with mood disorders, or similar effects in preclinical animal models. Overall, an improved understanding of the neurobiological underpinnings of mood disorders is critical in order to develop targeted treatments that are more effective, act more rapidly, and are better tolerated than currently available therapies. |
| format | Article |
| id | doaj-art-3d49ec8e460041fcb8c1f9378490a6b0 |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-3d49ec8e460041fcb8c1f9378490a6b02025-02-03T05:58:58ZengWileyThe Scientific World Journal1537-744X2010-01-011071372610.1100/tsw.2010.65New Therapeutic Targets for Mood DisordersRodrigo Machado-Vieira0Giacomo Salvadore1Nancy DiazGranados2Lobna Ibrahim3David Latov4Cristina Wheeler-Castillo5Jacqueline Baumann6Ioline D. Henter7Carlos A. Zarate8Experimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USAExperimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USAExperimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USAExperimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USAExperimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USAExperimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USAExperimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USAExperimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USAExperimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USAExisting pharmacological treatments for bipolar disorder (BPD) and major depressive disorder (MDD) are often insufficient for many patients. Here we describe a number of targets/compounds that clinical and preclinical studies suggest could result in putative novel treatments for mood disorders. These include: (1) glycogen synthase kinase-3 (GSK-3) and protein kinase C (PKC), (2) the purinergic system, (3) histone deacetylases (HDACs), (4) the melatonergic system, (5) the tachykinin neuropeptides system, (6) the glutamatergic system, and (7) oxidative stress and bioenergetics. The paper reviews data on new compounds that have shown antimanic or antidepressant effects in subjects with mood disorders, or similar effects in preclinical animal models. Overall, an improved understanding of the neurobiological underpinnings of mood disorders is critical in order to develop targeted treatments that are more effective, act more rapidly, and are better tolerated than currently available therapies.http://dx.doi.org/10.1100/tsw.2010.65 |
| spellingShingle | Rodrigo Machado-Vieira Giacomo Salvadore Nancy DiazGranados Lobna Ibrahim David Latov Cristina Wheeler-Castillo Jacqueline Baumann Ioline D. Henter Carlos A. Zarate New Therapeutic Targets for Mood Disorders The Scientific World Journal |
| title | New Therapeutic Targets for Mood Disorders |
| title_full | New Therapeutic Targets for Mood Disorders |
| title_fullStr | New Therapeutic Targets for Mood Disorders |
| title_full_unstemmed | New Therapeutic Targets for Mood Disorders |
| title_short | New Therapeutic Targets for Mood Disorders |
| title_sort | new therapeutic targets for mood disorders |
| url | http://dx.doi.org/10.1100/tsw.2010.65 |
| work_keys_str_mv | AT rodrigomachadovieira newtherapeutictargetsformooddisorders AT giacomosalvadore newtherapeutictargetsformooddisorders AT nancydiazgranados newtherapeutictargetsformooddisorders AT lobnaibrahim newtherapeutictargetsformooddisorders AT davidlatov newtherapeutictargetsformooddisorders AT cristinawheelercastillo newtherapeutictargetsformooddisorders AT jacquelinebaumann newtherapeutictargetsformooddisorders AT iolinedhenter newtherapeutictargetsformooddisorders AT carlosazarate newtherapeutictargetsformooddisorders |